Response To Ado-Trastuzumab Emtansine According To Rano Criteria In Central Nervous System Metastases Of Her2 Positive Breast Cancers.

605Background: Central nervous system (CNS) metastases are frequent in Her2 positive breast cancers (BC). Local treatment remains the standard of care, however systemic treatments may also represent a therapeutic option. Ado-trastuzumab Emtansine (TDM1) significantly improves outcomes of Her2 positive BC patients (pts), but only a few data have been published on its impact on CNS metastases. This multicentric retrospective cohort aims to evaluate the efficacy/safety of TDM1 in this setting in the common practice. Methods: Data from 14 pts treated with TDM1 for CNS metastases of Her2 positive breast cancers since February 2013 were retrospectively collected in two sites. RANO criteria were used for the CNS evaluation and RECIST criteria for systemic evaluation, both performed every 9 weeks. Safety was evaluated according to the NCI-CTC criteria. Results: Median age was 48.6 years (34.4-63.5). Median follow up was 12 months (mos) (5.4-35.9). Tumours were CCI (13/14) or CLI (1/14) and 10 (71%) expressed horm...